WHO preferred product characteristics for prevention of respiratory syncytial virus infection in infants and young children
10.13200/j.cnki.cjb.004539
- VernacularTitle:预防婴幼儿呼吸道合胞病毒感染的世界卫生组织理想产品特性
- Author:
LI Yufeng
- Publication Type:Journal Article
- Keywords:
Respiratory syncytial virus(RSV);
Vaccine;
Monoclonal antibodies(mAbs);
World Health Organization(WHO);
Preferred product characteristics(PPCs)
- From:
Chinese Journal of Biologicals
2025;38(08):976-984
- CountryChina
- Language:Chinese
-
Abstract:
Respiratory syncytial virus(RSV) is one of the main pathogens of lower respiratory tract infections. Although people of all ages can be infected with RSV, the illness tends to be more severe in infants, especially in premature infants,children with chronic lung disease or congenital heart disease, and the elderly, with the majority of the disease burden located in low-and middle-income countries(LMICs). The global availability of safe and effective vaccines is an established principle of the World Health Organization(WHO). Based on this principle, the WHO held two consultations in March 2015and April 2016 to discuss preventive interventions and advance the development of immunoprevention products for RSV infections. In 2017 and 2021, the WHO announced the preferred product characteristics(PPCs) for RSV vaccines and monoclonal antibodies(mAbs). Combined with the relevant guidelines from the WHO and countries with mature research and development, as well as existing market products, this paper comprehensively elaborates on the PPCs recommended by the WHO for immunoprevention products, RSV vaccines and mAbs.
